Clene (NASDAQ: CLNN) CEO and CFO Present at 72nd Emerging Growth Conference – InvestorBrandNetwork (IBN) Content Platform

Clene’s CEO Rob Etherington and CFO Morgan Brown presented highlights and updates on the company’s pipeline – as well as answering questions from the audience
Clene has conducted several clinical trials to test the efficacy of CNM-Au8(R), focusing on the diseases amyotrophic lateral sclerosis and multiple sclerosis
CNM-Au8 has shown a favorable safety profile, with over 650 collective years of subject exposure without any major safety signals attributed to CNM-Au8
Negotiations are underway to extend the cash runway into 2025, including potential licensing deals and the exercise of warrants that could bring in up to $130 million in additional capital for the company

Clene (NASDAQ: CLNN), a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), recently participated in the 72nd Emerging Growth Conference. EmergingGrowth.com is a leading independent small cap media portal that identifies companies with strong management teams, innovative products, focused strategy and overall potential for long-term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts. Clene’s CEO Rob Etherington and CFO Morgan Brown presented highlights and updates on the company’s pipeline – as well as answering questions from the audience.

The Emerging Growth Conference, moderated by award-winning journalist Ana Berry, is considered an effective way for public companies to engage with the investment community. Companies present new products, services, and make other announcements significant to their industry. During the event…